文献速递肿瘤 PET/CT核素与放射性配体治疗

CXCR4靶向68Ga-Pentixafor PET/CT列线图预测单侧原发性醛固酮增多症术后临床成功

Development and validation of a CXCR4-targeted 68 Ga-Pentixafor PET/CT-based nomogram for predicting postoperative clinical success in unilateral primary aldosteronism.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-03

本研究回顾性纳入109例接受肾上腺切除术的单侧原发性醛固酮增多症患者,基于术前临床特征和68Ga-Pentixafor PET/CT参数构建列线图预测术后6个月临床结局。最终模型纳入6个术前预测因子,训练队列AUC为0.90(95%CI 0.83–0.97),验证队列AUC为0.80(95%CI 0.62–0.97),校准良好且具有显著临床净获益,风险分层显示清晰梯度分离。

要点

  • 109例中64例(58.7%)术后6个月达到完全临床成功。
  • 最终模型纳入年龄、高血压病程、LLR R、SULmax R、LI2 R和SULmean共6个术前预测因子。
  • 列线图在训练和验证队列中均表现出良好区分度与校准,可用于术前风险分层。

核心结论

  • 联合临床特征与68Ga-Pentixafor PET/CT参数的列线图可作为术前工具,区分肾上腺切除术后达到完全临床成功的患者与仍需持续降压治疗的患者。

研究设计与样本

  • 回顾性纳入109例接受肾上腺切除术的单侧原发性醛固酮增多症患者,收集术前68Ga-Pentixafor PET/CT参数、临床资料及术后6个月手术结局。
  • 采用后向逐步回归结合赤池信息量准则(AIC)筛选预测因子并构建列线图,通过ROC曲线、校准图、决策曲线分析(DCA)和多模型比较评估模型性能,并进行风险分层。

主要发现

  • 109例患者中64例(58.7%)达到完全临床成功。
  • 最终模型纳入6个术前预测因子:年龄、高血压病程、LLR R、SULmax R、LI2 R和SULmean。
  • 训练队列AUC为0.90(95%CI 0.83–0.97),验证队列AUC为0.80(95%CI 0.62–0.97),校准良好且临床净获益显著。
  • 风险分层显示清晰的梯度分离和较强的临床可行性。

临床怎么用

  • 对于单侧原发性醛固酮增多症患者,术前可利用该列线图整合临床特征与68Ga-Pentixafor PET/CT参数,预测肾上腺切除术后6个月完全临床成功的概率,辅助治疗决策与风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary aldosteronism represents the most common and treatable form of secondary hypertension. Although over 90% of patients achieve resolution of hypokalemia post-operatively, nearly half still require antihypertensive medications. This study aimed to develop and validate a nomogram integrating preoperative clinical characteristics and CXCR4 targeted 68 Ga-Pentixafor PET/CT parameters to predict postoperative clinical outcomes in UPA. METHODS: A total of 109 UPA patients underwent adrenalectomy were retrospectively collected with preoperative 68 Ga-Pentixafor PET/CT parameters, clinical data and surgical outcomes at 6 months. Predictors identified by backward stepwise regression were incorporated into a nomogram based on the Akaike information criterion (AIC). Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA), and multi-model comparison. Risk stratification was further performed to explore the model’s clinical applicability. RESULTS: Among 109 patients, 64 (58.7%) achieved complete clinical success. Six presurgical predictors (age, duration of hypertension, LLR R, SULmax R, LI2 R, and SULmean) were included in the final model. The model demonstrated excellent discrimination (AUC 0.90, 95% CI 0.83–0.97 in the training cohort; 0.80, 95% CI 0.62–0.97 in the validation cohort) with good calibration and significant clinical net benefit. Risk stratification further revealed clear gradient separation and strong clinical feasibility. CONCLUSION: The proposed nomogram combining clinical and 68 Ga-Pentixafor PET/CT parameters serves as a robust preoperative tool for accurately distinguishing patients who will achieve complete clinical success after adrenalectomy from those requiring ongoing antihypertensive therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jin Y, Yang Y, Yang Y, et al. Development and validation of a CXCR4-targeted 68 Ga-Pentixafor PET/CT-based nomogram for predicting postoperative clinical success in unilateral primary aldosteronism. Eur J Nucl Med Mol Imaging. 2026. PMID: 41629417. doi:10.1007/s00259-026-07789-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。